Journal of the Korean Ophthalmological Society 2004;45(7):1099-1105.
Published online July 1, 2004.
Antiproliferative Effect and Safety of 5-Fluorouracil and Heparin in the Treatment of Proliferative Vitreoretinopathy.
Ki Hwan Choi, Sang Kook Kim, Se Woong Kang
1Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. swkang@smc.samsung.co.kr
2Department of Ophthalmology, Chungbuk National University College of Medicine, Cheongju, Korea.
5-Fluorouracil과 Heparin 혼합액의 증식유리체망막병증에 대한 억제효과 및 안전성
최기환 ( Ki Hwan Choi ) , 김상국 ( Sang Kook Kim ) , 강세웅 ( Se Woong Kang )
Abstract
PURPOSE
Proliferative vitreoretinopathy (PVR) is a major cause of recurrence and failure after retinal reattachment surgery. We assessed the effect and safety of adjuvant combination therapy using 5-Fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of PVR after vitrectomy. METHODS: Infusion fluid supplemented with 200 micro gram/mln of 5-FU and 5 IU/ml of LMWH was used during vitrectomy for rhegmatogenous retinal detachment in 21 patients with PVR. Anatomical results, the occurrence of postoperative PVR, and best corrected visual acuity were assessed retrospectively after a minimum of 6-month follow-up. The occurrence of complication was investigated in 27 eyes including an additional 6 eyes without PVR. RESULTS: The primary success rate was 85.7% (18/21) and the incidence of postoperative PVR was 14.3% (3/21). There was hyphema or vitreous hemorrhage in 3 eyes (14.3%), and significant corneal edema in 1 eye (4.8%) immediately after operation. Those complications were resolved without surgical management. There was intraocular pressure elevation (47.6%), and progression of cataract (23.8%) after operation. Those were controlled with antiglaucoma medication or operation. CONCLUSIONS: The use of 5-FU and LMWH is relatively safe and is suggested to have an antiproliferative effect.
Key Words: 5-Fluorouracil;Heparin;Proliferative vitreoretinopathy


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next